CD19 and neoplasm: In a clinical trial for CD19+ relapsed or refractory lymphoma, autologous CD19-directing CAR-T therapy showed a significant durable tumor remission (86%–89%) during a median follow-up of 28.6 months in patients who had an initial response (55).